Biotech Startups

Jungla develops computational and functional methods to interpret human genetic variants, combining clinical knowledge with auditable evidence from cellular assays and physics-based and computational models. The company aims to provide quantitative clinical guidance to support molecular diagnostic, screening, and therapeutic decision tests.

1 investor

A biosciences company combining targeted diagnostics and therapeutic delivery to improve outcomes in oncology.

1 investor

Juniper Biomedical develops minimally invasive implantable medical devices using neuromodulation technology to treat pelvic health conditions. The company addresses unmet clinical needs in urinary incontinence and other pelvic floor disorders for patients and healthcare providers.

1 investor

Juno Pharma Canada Inc. is a pharmaceutical company formed in April 2025 through the merger of Juno Pharmaceuticals Corp. and Omega Laboratories Limited. It operates in the Canadian pharmaceutical industry.

1 investor

Jupiter Neurosciences is a biopharmaceutical company developing JOTROL, a patented micellar oral formulation of resveratrol designed to cross the blood-brain barrier for central nervous system treatment. Its focus is developing therapies for Alzheimer's disease and rare "orphan" diseases.

1 investor

Jura Health offers at-home genetic testing (saliva or cheek swab) with telehealth genetic counseling to diagnose rare diseases, delivering results in about five weeks along with guidance on next steps. It serves patients and families seeking answers about undiagnosed rare conditions.

1 investor

1 investor

K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials. Its pipeline focuses on first- and best-in-class cell therapies for solid tumors, including a PRAME-targeting therapy for cutaneous melanoma and synovial sarcoma.

1 investor

K2bio operates a fully equipped, AAALAC-accredited contract vivarium facility in Houston supporting preclinical research for biotechnology and pharmaceutical companies. The facility provides flexible access to animal housing, technical services, imaging systems, and expertise across multiple therapeutic modalities including biologics, small molecules, and cell therapies.

1 investor

Kadence Bio is a clinical-stage life sciences company developing therapeutics for conditions in sexual and mental health. Its lead asset, KH-001, is being developed as an FDA-approved treatment for premature ejaculation, alongside a pipeline of compounds targeting mood disorders.

1 investor

Kadis Bio develops human induced pluripotent stem cell (hiPSC) therapies for treating cardiovascular disease, targeting peripheral arterial disease and critical limb ischemia. Its approach aims to promote blood vessel growth for conditions such as ischemic heart disease, diabetic retinopathy and neuropathy, and wound healing.

1 investor

Kaigene is a Maryland biotechnology company developing therapeutic antibodies and fusion proteins for rare autoimmune diseases.

1 investor

Kailos Genetics is a biotechnology company with expertise in medical and biotechnology industries.

1 investor

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion. Its lead asset is an engineered dual-targeting biologic aimed at longer-lasting anti-VEGF activity to reduce the frequency of injections for patients.

1 investor

Kalevala Therapeutics identifies drug repurposing opportunities for rare disease indications, aligning with clinical and advocacy partners to map regulatory pathways and pursue approval for new therapeutic uses. It operates in the biotech and drug development sector.

1 investor

Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention. The company's lead program targets genetic drivers of cardiovascular risk to deliver durable risk reduction in patients.

1 investor

Kalia Health is a biotechnology startup developing a home-based urine test that detects elevated protein levels to screen for preeclampsia and eclampsia early in pregnancy. It targets women's and maternal healthcare for low-resource settings in the United States and globally.

1 investor

Kalion manufactures high-purity glucaric acid and glucuronic acid for use as corrosion inhibitors, polymer additives, and ingredients in pharmaceuticals, nutraceuticals, and energy drinks. The company serves formulators and manufacturers across cleaning, concrete, water treatment, polymers, and pharmaceutical applications.

1 investor

KaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.

1 investor

Kalohexis is a biopharmaceutical company developing treatments that target the melanocortin system, the body's regulator of metabolic homeostasis, to address metabolic disorders beginning with obesity and cancer cachexia. Its therapies aim to adjust the body's metabolic set-point for patients with metabolic disease.

1 investor

Kamada is a vertically integrated biopharmaceutical company that develops and manufactures plasma-derived therapeutics for specialty markets. The company commercializes its own branded products including GLASSIA and KEDRAB, as well as acquired hyperimmune products, distributing to over 30 countries globally.

1 investor

Kaminari Medical develops intravascular imaging technology for cardiovascular interventions, using photoacoustic and optical innovations. The company serves interventional cardiologists and vascular surgeons for real-time imaging during catheter-based procedures.

1 investor

Karydo TherapeutiX is a Japanese therapeutics company operating in the biotech and drug discovery space. The page presents its corporate governance and scientific leadership without further detail on its products.

1 investor

Kasvu is a drug-discovery company developing small-molecule neuroplastogens — selective positive allosteric modulators of the TrkB receptor — using an AI-powered 3D model of the receptor and structure-based drug design. Its molecules aim to improve neuronal plasticity and cognitive function as treatments for neuropsychiatric conditions and neurodegenerative diseases such as Alzheimer's and Parkinson's.

1 investor